A Phase 1 interventional study of LOXO-305 and Itraconazole in Healthy Volunteers, sponsored by Loxo Oncology, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-09.
Sponsored by Loxo Oncology, Inc. (part of Eli Lilly and Company) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to learn about how itraconazole and rifampin affect LOXO-305 in healthy participants. Participation could last about 8 weeks.
Loxo Oncology, Inc. is the lead sponsor of 17 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
First submitted after Loxo Oncology, Inc. became part of Eli Lilly and Company.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History or presence of any of the following, deemed by the Investigator (or designee), and/or Sponsor:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Day 1: a single oral dose of 200 milligrams (mg) LOXO-305 was administered. * Day 8: oral doses of 200 mg itraconazole was administered twice daily. * Days 9 to 18: single oral dose of 200 mg itraconazole was administered once daily, and on Day 12 it was co-administered with a single oral dose of 200 mg LOXO-305.
Drug: LOXO-305 · Drug: Itraconazole
* Day 1: a single oral dose of 200 mg LOXO-305 was administered. * Days 8 to 23: oral dose of 600 mg rifampin was administered once daily, and on Days 8 \& 17, it was co-administered with a single oral dose of 200 mg LOXO-305.
Drug: LOXO-305 · Drug: Rifampin
Oral LOXO-305
Also known as: Pirtobrutinib
Oral itraconazole
Oral rifampin
Part 1: Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of LOXO-305
Cmax of LOXO-305
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on days 1 and 12
Part 1: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of LOXO 305
PK: AUC0-t of LOXO 305
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on days 1 and 12
Part 1: PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of LOXO-305
AUC0-inf of LOXO-305
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on days 1 and 12
Part 2: PK: Maximum Observed Plasma Concentration (Cmax) of LOXO-305
Cmax of LOXO-305
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on days 1 and 17; Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose on day 8
Part 2: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of LOXO 305
PK: AUC0-t of LOXO 305
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on days 1 and 17; Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose on day 8
Part 2: PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of LOXO-305
AUC0-inf of LOXO-305
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on days 1 and 17
Part 2: PK: Area Under the Concentration Versus Time Curve From Time Zero to 24 Hours Postdose (AUC0-24) of LOXO-305
AUC0-24 of LOXO-305
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose on days 1 and 8
| Milestone | Part 1 (LOXO-305/Itraconazole) | Part 2 (LOXO 305/Rifampin) |
|---|---|---|
| Started | 15 | 12 |
| Received at least one dose of study drug | 15 | 12 |
| Completed | 12 | 12 |
| Not completed | 3 | 0 |
| Withdrew: Subject discontinued out of precaution due to covid-19 | 3 | 0 |
Cmax of LOXO-305
| nanogram per milliliter (ng/mL) | Part 1 (LOXO-305/Itraconazole) |
|---|---|
| Day 1 | 4000 ± 23.5 |
| Day 12 | 4100 ± 17.2 |
PK: AUC0-t of LOXO 305
| hour*nanogram per milliliter (h*ng/mL) | Part 1 (LOXO-305/Itraconazole) |
|---|---|
| Day 1 | 80000 ± 23.4 |
| Day 12 | 122000 ± 22.7 |
AUC0-inf of LOXO-305
| hour*nanogram per milliliter (h*ng/mL) | Part 1 (LOXO-305/Itraconazole) |
|---|---|
| Day 1 | 80800 ± 23.4 |
| Day 12 | 123000 ± 23.4 |
Cmax of LOXO-305
| nanogram per milliliter (ng/mL) | Part 2 (LOXO 305/Rifampin) |
|---|---|
| Day 1 | 4480 ± 20.4 |
| Day 8 | 4170 ± 15.6 |
| Day 17 | 2580 ± 22.4 |
PK: AUC0-t of LOXO 305
| hour*nanogram per milliliter (h*ng/mL) | Part 2 (LOXO 305/Rifampin) |
|---|---|
| Day 1 | 79700 ± 17.6 |
| Day 8 | 48500 ± 14.7 |
| Day 17 | 23000 ± 20.1 |
AUC0-inf of LOXO-305
| hour*nanogram per milliliter (h*ng/mL) | Part 2 (LOXO 305/Rifampin) |
|---|---|
| Day 1 | 80600 ± 17.3 |
| Day 17 | 23600 ± 19.8 |
AUC0-24 of LOXO-305
| hour*nanogram per milliliter (h*ng/mL) | Part 2 (LOXO 305/Rifampin) |
|---|---|
| Day 1 | 50200 ± 14.5 |
| Day 8 | 48600 ± 14.7 |
Collected over Baseline to Follow-up (up to day 28 for Part 1; up to day 33 for Part 2). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: 200 mg LOXO-305 Alone | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) |
| Part 1: 200 mg Itraconazole Alone | 0/12 (0%) | 0/12 (0%) | 2/12 (16.7%) |
| Part 1: 200 mg LOXO-305 + 200 mg Itraconazole | 0/12 (0%) | 0/12 (0%) | 1/12 (8.3%) |
| Part 2: 200 mg LOXO-305 Alone | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) |
| Part 2: 200 mg LOXO-305 (Day 8) + 600 mg Rifampin | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) |
| Part 2: 200 mg LOXO-305 (Day 17) + 600 mg Rifampin | 0/12 (0%) | 0/12 (0%) | 1/12 (8.3%) |
| Event | Part 1: 200 mg LOXO-305 Alone | Part 1: 200 mg Itraconazole Alone | Part 1: 200 mg LOXO-305 + 200 mg Itraconazole | Part 2: 200 mg LOXO-305 Alone | Part 2: 200 mg LOXO-305 (Day 8) + 600 mg Rifampin | Part 2: 200 mg LOXO-305 (Day 17) + 600 mg Rifampin |
|---|---|---|---|---|---|---|
| Abdominal distensionGastrointestinal disorders | 0/15 | 0/12 | 0/12 | 0/12 | 0/12 | 1/12 |
| Aphthous ulcerGastrointestinal disorders | 0/15 | 1/12 | 0/12 | 0/12 | 0/12 | 0/12 |
| DiarrhoeaGastrointestinal disorders | 0/15 | 1/12 | 0/12 | 0/12 | 0/12 | 1/12 |
| EructationGastrointestinal disorders | 0/15 | 0/12 | 0/12 | 0/12 | 0/12 | 1/12 |
| NauseaGastrointestinal disorders | 0/15 | 1/12 | 0/12 | 0/12 | 0/12 | 0/12 |
| Arthropod biteInjury, poisoning and procedural complications | 0/15 | 1/12 | 0/12 | 0/12 | 0/12 | 0/12 |
| Muscle twitchingMusculoskeletal and connective tissue disorders | 0/15 | 0/12 | 1/12 | 0/12 | 0/12 | 0/12 |
All enrolled participants.
| Age, Continuous(years) | Part 1 (LOXO-305/Itraconazole) | Part 2 (LOXO 305/Rifampin) | Total |
|---|---|---|---|
| Mean | 37.9 ± 9.13 | 40.9 ± 7.79 | 39.2 ± 8.54 |
| Sex: Female, Male(Participants) | Part 1 (LOXO-305/Itraconazole) | Part 2 (LOXO 305/Rifampin) | Total |
|---|---|---|---|
| Female | 3 | 2 | 5 |
| Male | 12 | 10 | 22 |
| Ethnicity (NIH/OMB)(Participants) | Part 1 (LOXO-305/Itraconazole) | Part 2 (LOXO 305/Rifampin) | Total |
|---|---|---|---|
| Hispanic or Latino | 10 | 11 | 21 |
| Not Hispanic or Latino | 5 | 1 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1 (LOXO-305/Itraconazole) | Part 2 (LOXO 305/Rifampin) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 6 | 1 | 7 |
| White | 9 | 11 | 20 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Part 1 (LOXO-305/Itraconazole) | Part 2 (LOXO 305/Rifampin) | Total |
|---|---|---|---|
| United States | 15 | 12 | 27 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2020 to primary completion in Oct 2020, 8 months.
Results were first posted in Jan 2025, 4 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pirtobrutinib